Innocan Pharma - CEO Iris Bincovish
CEO Iris Bincovish
Source: Innocan Pharma
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Innocan Pharma Corporation (INNO) has filed a new patent application (PCT) entitled “compositions for treatment of diabetic symptoms”
  • This application increases Innocan’s health and wellness IP portfolio to 14
  • Innocan’s PCT involves a cannabinoid-based composition which can be used to improve circulation and thereby treat ailments associated with diabetes
  • Innocan is a pharmaceutical technology company that focuses on the development of several drug delivery platforms containing Cannabidiol (CBD)
  • InnoCan Pharma Corporation (INNO) opened trading at C$0.50 per share

Innocan Pharma (INNO) has filed a new patent application entitled “compositions for treatment of diabetic symptoms.”

This application increases Innocan’s health and wellness IP portfolio to 14.

The company expects that the application will result in more comprehensive international protection for its intellectual property in the United States and the EU.

Diabetes is a condition associated with the body’s production or use of insulin, which can have implications for circulation.

Data from the International Diabetes Federation shows that as of 2021, 537 million people – about 10 per cent of all people aged 20-79 in the world – were living with diabetes.  This number is expected to increase to 643 million by 2030 and 783 million by 2045.

Innocan’s PCT involves a cannabinoid-based composition which can be used to improve circulation and thereby treat ailments associated with diabetes.

The global creams and lotions for diabetic foot care market alone was valued at US$334.66 million in 2019 and is expected to grow at a compound annual growth rate of 7.7 per cent during the 2020-2029.

“Millions of people are suffering from diabetes, and the implications of the disease. We are determined to bring our proprietary solution to the market in order to address these issues and help ease the pain of those suffering,” stated Innocan CEO, Iris Bincovich.

Innocan is a pharmaceutical technology company that focuses on the development of several drug delivery platforms containing Cannabidiol (CBD).

InnoCan Pharma Corporation opened trading at C$0.50 per share.


More From The Market Herald
Medicenna - President and CEO, Fahar Merchant.

" Medicenna (TSX:MDNA) closes US$20 million public offering

Medicenna Therapeutics Corp. (MDNA) has closed its

" Aleafia Health (TSX:AH) earns record quarter-over-quarter revenue in Q1 2023

Aleafia Health (AH) reported its financial results for the three months ended June 30, 2022.

" UniDoc (CSE:UDOC) signs agreement to provide telehealth services in Kenya

UniDoc Health (UDOC) has signed a master equipment deployment and services agreement with Claron Health to provide telehealth services in Kenya.
InnoCan - Founder and CEO, Iris Bincovich.

" Innocan Pharma (CSE:INNO) approaches 100 per cent CBD bioavailability for its LPT CBD liposomal delivery platform

Innocan Pharma (INNO) has announced results from a clinical study on dogs suffering from pain.